Drug Use-Results Survey of OneCrinone 90 mg Vaginal Gel

Drug Use-Results Survey of OneCrinone 90 mg Vaginal Gel - Drug Use-Results Survey of OneCrinone

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036913

Enrollment

430

Registered

2019-06-03

Start date

2017-09-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Luteal support as a part of assisted reproductive technology

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients who receive treatment with this product for the approved indication of "Luteal support as a part of assisted reproductive technology" and who have been given informed consent.

Exclusion criteria

Exclusion criteria: Patients with contraindications in the package insert.

Design outcomes

Primary

Measure	Time frame
The incidence of adverse drug reactions and infections, the incidence of serious adverse events, and so on	—

Countries

Japan

Contacts

Public ContactTatsuya Ogura

Merck Biopharma Co., Ltd PMS Planning & Strategy, Medical Department

tatsuya.ogura@merckgroup.com03-6756-0750

Outcome results